Dr. Philip Band is the Research Professor of Orthopaedic Surgery, Biochemistry, and Molecular Pharmacology in the NYU School of Medicine. He is widely acknowledged as an expert on osteoarthritis, the extracellular matrix, hyaluronan, synovial fluid and intra-articular injection therapies. Dr Band founded and directed the Clinical Research Center at the NYU Hospital for Joint Diseases, and was a co-founder of the Joint Preservation and Arthritis Center. Dr. Band is also the Chief Executive Officer of CytoDel LLC, a biopharmaceutical company spun out of technology he co-developed at NYU. CytoDel has engineered recombinant derivatives of botulinum neurotoxin (BoNT) to create therapeutic fusion proteins, designed to deliver single chain antibodies to the inside of neurons. CytoDel’s lead product, Cyto-111, is a countermeasure against weaponized BoNT, which uses a single chain antibody to inactivate BoNT that has entered neurons. Cyto-111 is the first drug ever to reverse symptoms of botulism in animals.